首页 > 文章详情

AACR 十一月期刊编辑精选集

2020年12月16日

来源：癌症研究全球资讯

AACR十一月期刊编辑精选的主要内容是十篇由AACR旗下期刊的编辑们精心挑选的“必读”文章的集合。这些文章在有限的时间内提供免费阅读。请点击文末阅读原文，原文中提供的链接可免费阅读精选文章。

As we enter the winter holiday season, it’s time for the latest edition of Editors’ Picks, our monthly staple in which we highlight the “must read” articles chosen by the journal editors from each issue published by the American Association for Cancer Research. This month, selections range from a comparison of persistent opioid use following major surgery among patients with and without cancer, results from two clinical trials, and the preclinical development of an antibody-drug conjugate, among others. As always, studies featured here are freely available for a limited time.

Journal: Cancer Research (November 1 issue)

A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer

Pancreatic cancer is a lethal disease with limited response to several therapies, including immunotherapy. Due to the prevalence of epigenetic mutations in pancreatic cancers, epigenetic-modifying drugs have been explored as potential therapies. The authors previously found that the DNA hypomethylating drug decitabine altered methylation in tumor and stromal cells, inhibited tumor cell proliferation, and increased survival in a mouse model of pancreatic cancer. In this study, the authors explored the benefit of combining decitabine with immune checkpoint inhibitors against either PD-1 or V-domain Ig suppressor of T-cell activation (VISTA). They found that mice treated with single-agent decitabine had increased levels of tumor-infiltrating lymphocytes and M2-polarized macrophages, increased PD-1 expression, and increased tumor necrosis. While mice treated with single-agent decitabine or single-agent immune checkpoint inhibition had modest improvements in survival, treatment with decitabine followed by either immune checkpoint inhibitor led to an additive inhibition of tumor growth and prolonged survival. The greatest improvement in survival was observed in mice treated with decitabine followed by the PD-1 inhibitor, which extended mean survival from 32 to 54 days, compared to decitabine alone. The authors conclude that decitabine increases tumor infiltration of immune cells and significantly prolongs survival in mice when combined with immune checkpoint inhibition. A related commentary can be found here.

Journal: Cancer Discovery

An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants

责任编辑：肿瘤资讯-亚楠
排版编辑：肿瘤资讯-亚楠

领新版指南，先人一步>>

查看详情

2020年12月17日

李孝楼

福建医科大学孟超肝胆医院 | 肿瘤内科

学习精选

2020年12月16日

崔艳东

叶县人民医院 | 肿瘤科

十一月期刊编辑精选